TREK-1 constitutively expressed in normal sinus mucosa is down-regulated in inflammatory sinus mucosa where it may be involved in defective epithelial and endothelial barrier integrity. These results suggest that TREK-1 activating compounds may be used therapeutically to maintain the epithelial and endothelial barrier integrity in chronic rhinosinusitis.
http://ift.tt/2z9Wi0g
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου